ArticleCancer discovery2021
Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 140 citations in OpenAlex.
- The immunology of human breast cancer.Nature reviews. Immunology · 2026Review
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
- Squamous-state excursions activate APOBEC3A in cancer.bioRxiv : the preprint server for biology · 2026Article
- Gene expression in immune cells infected with Orientia tsutsugamushi and the antigenic variability of 56-kDa type-specific antigen.Scientific reports · 2026Article
- Effects of thymidylate synthase inhibitors differ in genomic uracilation and mutagenic potential.Life science alliance · 2026Article
- Machine Learning-Driven Identification and In Vitro Validation of the APOBEC3B-ANLN Regulatory Axis in Adrenocortical Carcinoma.Endocrine · 2026Article
- APOBEC3C coordinates DDX5 in R-loop resolution and dynamic control of Chk1-mediated stress-responsive circuitry as a prerequisite for gemcitabine resistance in p53-deficient cells.Cell death & disease · 2026Article
- Preliminary Exploration of Fluvastatin Inhibiting Proliferation, Migration and Invasion of Lung Cancer Cells and Reversing Paclitaxel Resistance: Mechanism Exploration Based on Multi-Omics Analysis.Drug design, development and therapy · 2026Article
- Article
- Putrescine functions as a metabolic checkpoint in replication stress-induced senescence.Cellular and molecular life sciences : CMLS · 2025Article
- Nuclear DAB2IP regulates DNA replication initiation through activating PLK1-mediated HBO1 phosphorylation.Nucleic acids research · 2025Article
- RNase H-sensitive accumulation of APOBEC3B in a nucleolus after DNA damage.Bioscience reports · 2025Article
- BRCA2 deficiency and replication stress drive APOBEC3-Mediated genomic instability.Nature communications · 2025Article
- APOBEC3A-Induced DNA Damage Drives Polymerase θ Dependency and Synthetic Lethality in Cancer.bioRxiv : the preprint server for biology · 2025Article
- Activation and regulation of cGAS-STING signaling in cancer cells.Molecular cell · 2025Review
- Sensitization of cancer cells to DNA-damaging agents by expression of the REV1 C-terminal domain: Implications for chemotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Article
- Cancer cells subvert the primate-specific KRAB zinc finger protein ZNF93 to control APOBEC3B.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- TRDMT1 methyltransferase gene knockout attenuates STING-based cell death signaling during self-extracellular RNA-mediated response in drug-induced senescent osteosarcoma cells.Cellular and molecular life sciences : CMLS · 2025Article
- ASPM Induces Radiotherapy Resistance by Disrupting Microtubule Stability Leading to Chromosome Malsegregation in Non-Small Cell Lung Cancer.Exploration (Beijing, China) · 2025Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors at 17 institutions in 8 countries.
Subramanian VenkatesanCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0001-6454-8508
Mihaela AngelovaCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-0495-9695
Clare PuttickCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.
Haoran ZhaiCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, London, United Kingdom.
Deborah R CaswellCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-7550-5092
Wei-Ting LuCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-1405-4806
Michelle DietzenCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-6853-7563
Panagiotis GalanosGenome Integrity Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.ORCID 0000-0003-1403-4685
Konstantinos EvangelouMolecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Roberto BellelliCentre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Emilia L LimCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.
Thomas B K WatkinsCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.
Andrew RowanCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.
Vitor H TeixeiraLungs for Living Research Centre, UCL Respiratory, Division of Medicine, University College London, London, United Kingdom.
Yue ZhaoDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Haiquan ChenDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0003-1689-0549
Bryan NgoSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
Lykourgos-Panagiotis ZalmasOpen Targets Validation Lab, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.ORCID 0000-0002-4317-7709
Maise Al BakirCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.
Sebastijan HoborCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.
Eva GrönroosCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0001-8303-5409
Adam PennycuickLungs for Living Research Centre, UCL Respiratory, Division of Medicine, University College London, London, United Kingdom.ORCID 0000-0001-5836-0250
Ersilia NigroLungs for Living Research Centre, UCL Respiratory, Division of Medicine, University College London, London, United Kingdom.
Brittany B CampbellCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.
William L BrownMasonic Cancer Center, Minneapolis; Institute for Molecular Virology, Minneapolis; Center for Genome Engineering, Minneapolis, Minnesota.ORCID 0000-0001-5354-9468
Ayse U AkarcaDepartment of Histopathology, University College London, London, United Kingdom.ORCID 0000-0003-0629-3927
Teresa MarafiotiDepartment of Histopathology, University College London, London, United Kingdom.ORCID 0000-0003-1223-6275
Mary Y WuHigh Throughput Screening Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-2074-6171
Michael HowellHigh Throughput Screening Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0003-0912-0079
Simon J BoultonDSB Repair Metabolism Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-1125-8977
Cosetta BertoliMRC Laboratory for Molecular Cell Biology, University College London, London, United Kingdom.
Tim R FentonSchool of Biosciences, University of Kent, Canterbury, United Kingdom.ORCID 0000-0002-4737-8233
Robertus A M de BruinMRC Laboratory for Molecular Cell Biology, University College London, London, United Kingdom.ORCID 0000-0001-9957-1409
Apolinar Maya-MendozaGenome Integrity Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.ORCID 0000-0001-7452-9896
Eric Santoni-RugiuDepartment of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0002-2283-3535
Robert E HyndsCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-2170-8791
Vassilis G GorgoulisMolecular Carcinogenesis Group, Department of Histology and Embryology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0001-9001-4112
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, London, United Kingdom.
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, London, United Kingdom.
Reuben S HarrisMasonic Cancer Center, Minneapolis; Institute for Molecular Virology, Minneapolis; Center for Genome Engineering, Minneapolis, Minnesota.
Sam M JanesLungs for Living Research Centre, UCL Respiratory, Division of Medicine, University College London, London, United Kingdom.ORCID 0000-0002-6634-5939
Jirina BartkovaGenome Integrity Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.
Samuel F BakhoumHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. charles.swanton@crick.ac.uk samuel.bakhoum@gmail.com jb@cancer.dk n.kanu@ucl.ac.uk.
Jiri BartekGenome Integrity Unit, Danish Cancer Society Research Center, Copenhagen, Denmark. charles.swanton@crick.ac.uk samuel.bakhoum@gmail.com jb@cancer.dk n.kanu@ucl.ac.uk.
Nnennaya KanuCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, London, United Kingdom. charles.swanton@crick.ac.uk samuel.bakhoum@gmail.com jb@cancer.dk n.kanu@ucl.ac.uk.
Charles SwantonORCID 0000-0002-4299-3018
TRACERx Consortium
The Francis Crick Institute · GBLiving Streets · GBCRUK Lung Cancer Centre of Excellence · GBDanish Cancer Society · DKMRC Laboratory for Molecular Cell Biology · GBNational and Kapodistrian University of Athens · GRScience for Life Laboratory · SEShanghai Medical College of Fudan University · CNThe London College · GBUniversity College London Hospitals NHS Foundation Trust · GBUniversity of Minnesota · USCornell University · USMemorial Sloan Kettering Cancer Center · USQueen Mary University of London · GBUniversity of Copenhagen · DKUniversity of Kent · GBWellcome Sanger Institute · GB
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTargeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Simon N. Powell · 2020 to 2026
$16.3MPROJECT 3 – BIOLOGY OF DNA DEAMINASES IN CANCERP01CA234228 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Reuben S Harris · 2019 to 2026
$14.5MProbing cytosolic nucleic acid sensing pathways in cancerR01CA256188 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LAUGHNEY, ASHLEY MARIE · 2021 to 2025
$3.5MThe role of chromosomal instability in tumor evolutionDP5OD026395 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI BAKHOUM, SAMUEL F · 2018 to 2022
$2.2MCancer Research UK 17786Cancer Research UK 20147Cancer Research UK 20466Cancer Research UK 25253Cancer Research UK 30025Cancer Research UK FC001169European Research Council 617844European Research Council 835297Medical Research Council MC_EX_G0800785National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/S001832/1NCI NIH HHS P01 CA234228NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NCI NIH HHS R01 CA256188NIH HHS DP5 OD026395Wellcome Trust 209199/Z/17/ZWellcome Trust FC001169
Abstract
APOBEC3 enzymes are cytosine deaminases implicated in cancer. Precisely when
Indexed as
AnimalsAPOBEC DeaminasesBreast NeoplasmsCarcinoma, DuctalCarcinoma, Non-Small-Cell LungCell Line, TumorChromosomal InstabilityDNA ReplicationFemaleHumansLung NeoplasmsMiceAPOBEC3 proteins, humanAPOBEC Deaminases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.